Luteinising hormone is produced in the pituitary gland and stimulates ovulation and the production of oestrogen. LHRH agonists are molecules which mimic the action of luteinising Hormone by binding to the same receptors within the pituitary gland and thereby block the signal for ovarian production of oestrogen, which is known to stimulate the growth of breast cancer.
Professor Jack Cuzick, Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary’s School of Medicine and Dentistry, University of London, UK and colleagues found that for hormone receptor-positive patients, LHRH agonists were as effective as chemotherapy treatment used in these trials.
Treatment with LHRH agonists combined with chemotherapy or tamoxifen gave an additional benefit, reducing recurrence of breast cancer by nearly 13% and death after recurrence by 15%. However the combined treatments only showed the additional benefit in women under 40. LHRH agonists were ineffective for hormone receptor-negative tumours.
The researchers did a meta-analysis (a study which combines results from previous trials) of 16 trials and obtained data for 11,906 premenopausal women with early breast cancer.
The authors conclude: “The results of our analysis show that LHRH agonists provide an effective additional class of agents for the treatment of premenopausal women with hormone-sensitive breast cancer.”
In an accompanying Comment, Drs Nicholas Wilcken and Martin Stockler, Department of Medical Oncology, Westmead and Napean Hosptials and University of Sydney, NSW, Australia and NHMRC Clinical Trials Centre, University of Sydney and Sydney Cancer Centre, Royal Prince Alfred and Concord Hospitals, NSW, Australia, say: “In women with higher-risk disease, chemotherapy followed by tamoxifen should still be the standard approach, with the addition of an LHRH analogue a reasonable consideration for those who remain premenopausal.
“A century of research has taught us much about endocrine therapy for breast cancer, but the most important lessons about adjuvant ovarian suppression will be learnt over the next decade.”
Tony Kirby | alfa
Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State
NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy
08.12.2016 | Materials Sciences